Harness their
natural strength1,2
Consider ECP to modulate their
dysregulated immune system and support
them beyond just symptom control*3-6
*THERAKOS ECP Immunomodulation™ employs the patient's own immune cells to modulate disregulated immune function1-5,7-10.
The exact mechanism of action (MOA) of the photosensitising agent is unknown. Individual results may vary.
Harness their natural strength
What do you get when you choose THERAKOS ECP Immunomodulation™?
ECP Strength
- Evidence-based Treatment11-19
- Immunomodulation3-5
- Cost-effectiveness21-24
THERAKOS ECP EDGE
- CELLEX™ System Performance25,26
- Validated Technology11,26,27
- Patient & Customer Focus
- Access & Delivery Support
- The Therakos Institute
![Therakos Ecp Immunomodulation](/media/gp3looxe/therakos_ecp_immunomodulation.jpg?width=690&height=400&quality=70&meta=false&rnd=133264692289170000)
Therakos ECP Immunomodulation™
Find out more about our therapy and its clinical applications
![Cellex](/media/dr3odrkx/cellex.jpg?width=690&height=400&quality=70&meta=false&rnd=133264698142030000)
THERAKOS™ CELLEX™ Photopheresis System
Learn about the world’s only fully integrated and validated ECP system
![Research Opportunities Educational Grants](/media/xbbjlcl1/research-opportunities-educational-grants.jpg?width=690&height=400&quality=70&meta=false&rnd=133316551773400000)
Research Opportunities & Educational Grants
Discover educational grants and research opportunities available to you
![Health Economics](/media/jkzjv0hc/health-economics.jpg?width=690&height=400&quality=70&meta=false&rnd=133316551771730000)
Health Economics
Learn about the potential economic benefits of choosing CELLEXTM, and find out about our funding support services
![Customer Support](/media/htnlt4g2/customer-support.jpg?width=690&height=400&quality=70&meta=false&rnd=133316554233400000)
Customer Support
Get in touch with us
References
1. Operator’s Manual. THERAKOSTM CELLEXTM Photopheresis System. Therakos. 2019. 2. Hart JW, et al. Ther Adv Hematol. 2013;4:320-334. 3. Wang L, et al. Front Immunol. 2018;9:2207. 4. Ni M, et al. Front Immunol. 2019;10:547. 5. Mankarious M, et al. Front Immunol. 2020;11:81. 6. Dignan FL, et al. Bone Marrow Transplant. 2014;49(5):704-708. 7. Yoo EK, et al. J Invest Dermatol. 1996;107:235-242. 8. Morelli AE, et al. Blood. 2003;101:611-620. 9. Craciun LI, et al. Transplantation. 2002;74:995-1000. 10. Lamioni A, et al. Transplantation. 2005;79:846-850. 11. Knobler R, et al. J Eur Acad Dermatol Venereol. 2020;34(12):2693-2716. 12. Cho A, et al. Front Med (Lausanne). 2018;5:236. 13. Trautinger F, et al. Eur J Cancer. 2017;77:57-74. 14. Padmanabhan A, et al. J Clin Apher. 2019;34(3):171- 354. 15. Alfred A, et al. Br J Haematol. 2017;177:287-310. 16. Dignan FL, et al. Br J Haematol. 2012;158(1):30–45. 17. Pierelli L, et al. Transfusion. 2013;53(10):2340-2352. 18. Zeiser R. et al. Graft-versus-Host Erkrankung, akut. 2021. Available at: https://www.onkopedia.com/de/onkopedia/guidelines/graft-versus-host-erkrankung-akut/@@view/html/index.html. Accessed February 2022. 19. Costanzo MR, et al. J Heart Lung Transplant. 2010;29(8):914-956 20. Crespo C, et al. Clin Ther. 2012;34(8):1774-1787. 21. Walczak J, et al. Value Health. 2012;15:A349. 22. de Waure C, et al. Value Health. 2015;18(4):457-466. 23. Geskin L, Malone DC. J Dermatolog Treat. 2018;29(5):522-530. 24. Mayer W, et al. Retrospective data analysis related to the use of open and closed extracorporeal photopheresis systems. Presented at the 40th annual meeting of the American Society for Apheresis; 14-18 May, 2019, Portland, USA. Available at: https://doi.org/10.1002/jca.21704. Accessed November 2021. 25. Linic B, et al. The implementation of ‘lean’ working practices and THERAKOSTM CELLEXTM have resulted in a 50% increase in patient treatments with the same number of nurses employed in the unit. Presented at the 20th congress of the European Hematology Association; 11-14 June, 2015, Vienna, Austria. Poster E1428. 26. Therakos (UK) Ltd. Data on file - ref-06130. 27. Therakos (UK) Ltd. Data on file - ref-04301.